Aims: To review one year of ultrasound impulse elastometry in a hospital in Ouagadougou. Patients and Method: This is a retrospective descriptive study of data from one year’s use of impulse ultrasound elastometry. Ultrasound impulse elastometry was performed using the FibroScan？ COMPACT 530. Fibrosis was considered significant when E (hepatic elasticity) ≥ 7.2 kPa (F2 fibrosis). The test was considered valid when the IQR/Median ratio ≤ 30% and there were at least 10 valid measurements. Results: A total of 1911 patients underwent FibroScan？. There were 1079 men, giving a sex ratio of 1.3. The mean age of the patients was 37.9 ± 12.2 years. The indication for FibroScan？ was hepatitis B virus infection in 89% of cases. The validation criteria for FibroScan？ were met in all patients. The mean value for elasticity was 7.9 kPa and for steatosis 212 dB/m. Fibrosis was non-significant in 75.5% of cases. More than half of our patients (56.7%) didn’t have steatosis, 24.8% had mild steatosis, 12.4% had moderate steatosis and 6.1% had severe steatosis. Conclusion: Ultrasound pulse elastometry plays an important role in monitoring chronic liver disease. It allows non-invasive diagnosis of hepatic fibrosis and steatosis. In our context, however, access to the test is limited by its availability only in large urban centers, and by its cost.
References
[1]
Sandrin, L., Fourquet, B., Hasquenoph, J., Yon, S., Fournier, C., Mal, F., et al. (2003) Transient Elastography: A New Noninvasive Method for Assessment of Hepatic Fibrosis. Ultrasound in Medicine & Biology, 29, 1705-1713. https://doi.org/10.1016/j.ultrasmedbio.2003.07.001
[2]
Silvain, C. (2015) Le patient cirrhotique, une prise en charge complexe. La Revue de l'Infirmière, 64, 16-18. https://doi.org/10.1016/j.revinf.2014.10.010
[3]
Asselah, T., Ripault, M. and Marcellin, P. (2005) Hépatite chronique B: Qui traiter et comment ? Gastroentérologie Clinique et Biologique, 29, 374-383. https://doi.org/10.1016/s0399-8320(05)80784-5
[4]
European Association for the Study of the Liver (2012) EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B Virus Infection. Journal of Hepatology, 57, 167-185. https://doi.org/10.1016/j.jhep.2012.02.010
[5]
Spahr, L. (2012) Les tests non invasifs de fibrose vont-ils remplacer la biopsie hépatique? Revue Médicale Suisse, 8, 1411-1415. https://doi.org/10.53738/revmed.2012.8.347.1411
[6]
Alzon, A. (2022) FibroScan® GO Now Available in France. Echosens. https://www.echosens.com/fr/fibroscan-go-disponible-en-france/
[7]
Sandrin, L., Fournier, C., Miette, V., Yon, S. and Hasquenoph, J.M. (2006) Fibroscan®: Un outil non invasif de mesure de la dureté du foie par élastométrie. ITBM-RBM, 27, 25-31. https://doi.org/10.1016/j.rbmret.2005.07.006
[8]
Sokpon, M., Amrani, L., Salihoun, M., Acharki, M., Serraj, I., Amrani, N., et al. (2016) Évaluation initiale de la fibrose hépatique par le fibroscan chez les porteurs inactifs de l’AgHbs: À propos d’une étude monocentrique marocaine. Hegel, 3, 265-268. https://doi.org/10.3917/heg.063.0265
[9]
Hatrydt, G.D.K., Gogan, P., Yao-Bathaix, F.M., Mahassadi, A.K. and Koffi, A.A. (2024) Dépistage de la stéatose hépatique par le Fibroscan/CAP chez les sujets noirs Africains porteurs d’une Hépatite Virale B chronique en Côte d’Ivoire. Annales Africaines de Medecine, 17, e5495-e5504. https://doi.org/10.4314/aamed.v17i1.7
[10]
Diallo, M.S., Youssouf, O., Yaogo, A., Diallo, D., Diallo, K., Wann, T.A., et al. (2024) Evaluation of Hepatic Fibrosis and Hepatic Steatosis by Pulse Elastography (FIBROSCAN/CAP) in Asymptomatic Patients about 170 Cases at the Donka CHU National Hospital in Conakry. Open Journal of Gastroenterology, 14, 125-138. https://doi.org/10.4236/ojgas.2024.144014
[11]
INSD (2024) Results of the 5th General Census of Population and Housing. https://www.insd.bf/fr/resultats
[12]
Touré, P.S., Diop, M.M., Lô, G., Sow-Sall, A., Da Veiga, J.A., Sarr, M.M., et al. (2016) Intêret du FibroScan® et des marqueurs biologiques de la fibrose hépatique, chez des sénégalais porteurs chroniques du virus de l’hépatite B faiblement réplicatifs. Journal Africain d’Hépato-Gastroentérologie, 10, 14-20. https://doi.org/10.1007/s12157-015-0634-4
[13]
Eddowes, P.J., Sasso, M., Allison, M., Tsochatzis, E., Anstee, Q.M., Sheridan, D., et al. (2019) Accuracy of Fibroscan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology, 156, 1717-1730. https://doi.org/10.1053/j.gastro.2019.01.042
[14]
Sombié, R., Bougouma, A., Diallo, O., Bonkoungou, G., Cissé, R., Sangare, L., et al. (2010) Hépatite B chronique: Aspects épidémiologique, diagnostique, thérapeutique et évolutif au centre hospitalier universitaire Yalgado Ouédraogo de Ouagadougou. Journal Africain d’Hépato-Gastroentérologie, 4, 3-10. https://doi.org/10.1007/s12157-009-0137-2
[15]
Meda, N., Tuaillon, E., Kania, D., Tiendrebeogo, A., Pisoni, A., Zida, S., et al. (2018) Hepatitis B and C Virus Seroprevalence, Burkina Faso: A Cross-Sectional Study. Bulletin of the World Health Organization, 96, 750-759. https://doi.org/10.2471/blt.18.208603
[16]
Somé, E.N., Guingané, N.A., Lompo, I.T. and Sombié, R. (2021) Cirrhose du foie: Aspects épidémi-ologiques et diagnostiques au centre hospitalier universitaire Yalgado Ouédraogo. Revue des sciences sociales, 3, 53-64.
[17]
Wang CY, Lu W, Hu DS, Wang GD, Cheng XJ (2014) Diagnostic Value of Controlled Attenuation Parameter for Liver Steatosis in Patients with Chronic Hepatitis B. World Journal of Gastroenterology, 20, 10585-10590. https://doi.org/10.3748/wjg.v20.i30.10585
[18]
(2024) Prevalence of Obesity among Adults, BMI ≥ 30 (Age-Standardized Estimate) (%). https://www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence-of-obesity-among-adults-bmi-=-30-(age-standardized-estimate)-(-)
